# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Phase 3 PAPILLON study showed RYBREVANT® in combination with carboplatin and pemetrexed significantly improved progression-free...
Johnson & Johnson announced Phase 3 CARTITUDE-4 study results showing Carvykti significantly improves overall survival in r...
A federal judge has dismissed a Johnson & Johnson subsidiary's lawsuit against Dr. Jacqueline Moline, who linked talc p...
Ten of the Dow Jones Industrial Average stocks were up double digit percentage in the first half of 2024. A look at the best an...
A federal judge rejected a bid by cancer victims to block Johnson & Johnson from pursuing a $6.48 billion bankruptcy settle...
Cantor Fitzgerald analyst Louise Chen reiterates Johnson & Johnson (NYSE:JNJ) with a Overweight and maintains $215 price...
First-and-only FcRn blocker to demonstrate superiority in activities of daily living (MG-ADLa) over placebo when added to stand...